Comparative Pharmacology
Head-to-head clinical analysis: X TROZINE L A versus ZYRTEC D 12 HOUR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: X TROZINE L A versus ZYRTEC D 12 HOUR.
X-TROZINE L.A. vs ZYRTEC-D 12 HOUR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
X-TROZINE L.A. is a piperazine derivative that acts as a centrally acting alpha-2 adrenergic agonist, reducing sympathetic outflow from the brainstem, leading to decreased peripheral vascular resistance and lowered blood pressure.
Cetirizine is a second-generation antihistamine that selectively inhibits peripheral H1 receptors, reducing histamine-mediated allergic responses. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant via alpha-adrenergic receptor agonism in the respiratory tract mucosa, causing vasoconstriction and reduced edema.
250 mg orally once daily. May be increased to 500 mg once daily if needed.
1 tablet (5 mg cetirizine / 120 mg pseudoephedrine) orally every 12 hours. Maximum 2 tablets per 24 hours.
None Documented
None Documented
12-15 hours; prolonged in renal impairment (up to 30 hours in CrCl <30 mL/min).
Cetirizine: 8-10 hours in healthy adults; increased in renal impairment (e.g., up to 30 hours in severe impairment). Pseudoephedrine: 5-8 hours (pH-dependent; longer in alkaline urine).
Primarily renal (70-80% as unchanged drug), with 20-30% fecal via biliary excretion.
Cetirizine: 70% renal (unchanged), 10% fecal. Pseudoephedrine: 90% renal (unchanged), remainder metabolized and excreted in urine.
Category C
Category C
Antihistamine
Antihistamine and Decongestant Combination